Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TOP2A | P11388 | 4/20 | 0.46 |
| ▸ | TK1 | P04183 | 7/20 | 0.45 |
| ▸ | RNASE1 | P07998 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6926298 | 1.00 | TOP2A (0.46) | TOP2ATK1RNASE1 | |
| SCHEMBL6830845 | 1.00 | TOP2A (0.46) | TOP2ATK1RNASE1 | |
| SCHEMBL8424546 | 0.89 | TK1 (0.46) | TOP2ATK1RNASE1 | |
| SCHEMBL6827406 | 0.88 | TK1 (0.48) | TOP2ATK1RNASE1 | |
| SCHEMBL8903840 | 0.88 | TOP2A (0.46) | TOP2ATK1RNASE1 | |
| SCHEMBL14704109 | 0.87 | RNASE1 (0.47) | TOP2ATK1RNASE1 | |
| SCHEMBL14704124 | 0.87 | RNASE1 (0.47) | TOP2ATK1RNASE1 | |
| SCHEMBL22020930 | 0.87 | TK1 (0.49) | TOP2ATK1RNASE1 | |
| SCHEMBL22020934 | 0.87 | TK1 (0.49) | TOP2ATK1RNASE1 | |
| SCHEMBL6827423 | 0.86 | TOP2A (0.45) | TOP2ATK1RNASE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6743902-B1 | FOR USE IN ANTISENSE THERAPY FOR ENHANCING NUCLEASE RESISTANCE AND CELLULAR UPTAKE | VALEANT PHARMACEUTICALS INTERNATIONAL | 2004-06-01 | — | — | US | disclosed |
| US-6191266-B1 | MODIFIED TO COMPRISE SUBSTITUTIONS AT POSITIONS C1', C3', C4' OR C5' OF THE SUGAR MOIETY OF THE NUCLEOSIDE, INCLUDING AN OPTIONAL 3' PHOSPHOROAMIDITE GROUP; USE IN MAKING NUCLEASE RESISTANT OLIGONUCLEOTIDES FOR ANTISENSE THERAPY | ICN PHARMACEUTICALS, INC. | 2001-02-20 | — | — | US | disclosed |
| EP-0789706-A4 | SUGAR MODIFIED NUCLEOSIDES AND THEIR USE FOR SYNTHESIS OF OLIGONUCLEOTIDES | ICN PHARMACEUTICALS (US) | 1999-08-11 | — | — | EP | disclosed |
| US-5712378-A | SUGAR MOLECULE IS SUBSTITUTED WITH HYDROCARBON OR SUBSTITUTED HYDROCARBON GROUPS, ANTISENSE AGENTS | ICN PHARMACEUTICALS (US) | 1998-01-27 | — | — | US | disclosed |
| EP-0789706-A1 | SUGAR MODIFIED NUCLEOSIDES AND THEIR USE FOR SYNTHESIS OF OLIGONUCLEOTIDES | ICN PHARMACEUTICALS (US) | 1997-08-20 | — | — | EP | disclosed |
| WO-1996014329-A1 | SUGAR MODIFIED NUCLEOSIDES AND THEIR USE FOR SYNTHESIS OF OLIGONUCLEOTIDES | ICN PHARMACEUTICALS (US) | 1996-05-17 | — | — | WO | disclosed |